# UBS Oncology Impact Fund

> UBS Oncology Impact Fund is a VC fund backing Biotechnology, Therapeutics and Medical. See 6 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Total investments: 6
- Last investment: Sep 2019
- Lead investor: 33%
- Last updated: Aug 2026

UBS Oncology Impact Fund is a VC fund focused on Biotechnology and Therapeutics. UBS Oncology Impact Fund

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 4 | 67% |
| Therapeutics | 2 | 33% |
| Medical | 1 | 17% |
| Oncology | 1 | 17% |
| Biopharma | 1 | 17% |

10 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 50% |
| Series B | 2 | 33% |

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United States | 3 | 50% |
| Canada | 1 | 17% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Repare Therapeutics | Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells. The company's drugs combine a proprietary high throughput gene-editing and target discovery method with high-resolution protein crystallography, computational biology and clinical informatics, enabling patients to improve cancertreatment both with single therapy and in combination with existing drugs and treatments. | $82.5M | Series B | Sep 04, 2019 | http://www.reparerx.com/ |
| Oncorus | Oncorus, Inc. is a lean early-stage biotechnology company developing a next-generation immunotherapy platform to treat cancer. Oncorus was founded MPM Managing Director Mitch Finer, a well-known biotechnology entrepreneur. Oncorus is a leader in corporate philanthropy, and has taken a pledge to donate a portion of product sales to fund promisingcancer research and to support cancer care in the developing world. | $79.5M | Series B | Aug 21, 2019 | http://www.oncorus.com/ |
| ElevateBio | ElevateBio is an operator of a portfolio of cell and gene therapy companies intended to develop, manufacture, and commercialize life-transforming medicines.The company creates a portfolio through partnerships with the world's innovative scientists and inventors as well as it created a centralized facility that integrates all the elementsthat translate cell and gene therapy R&D into commercially viable therapies quickly and efficiently, enabling patients to get medical products to treat severe diseases.Vikas Sinha, Mitchell Finer, and David Hallal co-founded ElevateBio in Cambridge, Massachusetts in 2017. | $150M | Series A | May 13, 2019 | https://www.elevate.bio |
| Cullinan Therapeutics | Cullinan Therapeutics is a developer of an externally sourced cancer therapeutics intended to end a drug program quickly if the early research suggests it won't work. The company's therapeutics are developed via assets sourced internally through dry lab or externally through business, academic and pharma collaborations, enablingresearchers to get a highly diversified portfolio of oncology therapeutics with a unique, cost-efficient business model. | $150M | Series A | Oct 03, 2017 | https://www.cullinanoncology.com/ |
| Repare Therapeutics | Repare Therapeutics is a developer of oncology drugs designed to target specific vulnerabilities of tumor cells. The company's drugs combine a proprietary high throughput gene-editing and target discovery method with high-resolution protein crystallography, computational biology and clinical informatics, enabling patients to improve cancertreatment both with single therapy and in combination with existing drugs and treatments. | $68M | Series A | Jun 22, 2017 | http://www.reparerx.com/ |

5 of 6 investments shown.

## Co-investors
- [MPM Capital](https://shizune.co/investors/profile/mpm-capital) — VC Fund, 4 deals together
- [F2 Ventures](https://shizune.co/investors/profile/f2-ventures) — VC Fund, 3 deals together
- [Redmile Group](https://shizune.co/investors/profile/redmile-group) — VC Fund, 3 deals together
- [Celgene](https://shizune.co/investors/profile/celgene) — VC Fund, 2 deals together
- [Cowen Healthcare Investments](https://shizune.co/investors/profile/cowen-healthcare-investments) — VC Fund, 2 deals together
- [EcoR1 Capital](https://shizune.co/investors/profile/ecor1-capital) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does UBS Oncology Impact Fund invest in?

UBS Oncology Impact Fund invests primarily in Biotechnology, Therapeutics and Medical startups, most often at Series A and Series B stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did UBS Oncology Impact Fund last invest?

The most recent investment recorded for UBS Oncology Impact Fund closed in Sep 2019. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co